Mount Yale Investment Advisors LLC Sells 423 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mount Yale Investment Advisors LLC cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 4.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,559 shares of the medical equipment provider’s stock after selling 423 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in Hologic were worth $636,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its holdings in shares of Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after acquiring an additional 2,753,016 shares during the last quarter. Black Creek Investment Management Inc. lifted its stake in Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Hologic by 5.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after buying an additional 124,739 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Hologic by 4.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock worth $168,666,000 after buying an additional 87,176 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Hologic by 117.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock worth $154,598,000 after buying an additional 1,168,564 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HOLX has been the topic of several recent research reports. StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 18th. Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of Hologic in a report on Tuesday, September 17th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a research note on Friday, August 16th. Evercore ISI lifted their target price on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. upped their price target on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $87.60.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares of the company’s stock, valued at $3,615,024. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,280 shares of company stock valued at $1,469,973. 1.75% of the stock is currently owned by company insiders.

Hologic Trading Up 0.1 %

NASDAQ:HOLX opened at $81.46 on Tuesday. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The firm’s fifty day moving average is $80.90 and its 200-day moving average is $77.17. The firm has a market cap of $19.01 billion, a P/E ratio of 41.56, a P/E/G ratio of 2.53 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the prior year, the firm posted $0.93 earnings per share. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. Equities analysts expect that Hologic, Inc. will post 4.09 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.